BioMarin Pharma (BMRN): BMN-270 Update Is An Incremental Positive - Baird

October 14, 2016 7:58 AM EDT
Get Alerts BMRN Hot Sheet
Price: $83.30 -1.56%

Rating Summary:
    20 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade BMRN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Baird analyst, Michael Ulz, reiterated his Outperform on shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) on the heels of the BMN-270 update which he views as an incremental positive.

After the close, BioMarin announced that UK regulators approved continued enrollment in the Phase 1/2 study of BMN-270 (gene therapy) in Hemophilia A. Importantly, continuation indicates regulators are not overly concerned with Factor VIII expression above the normal range (two patients >150%) or ALT elevations. Additionally, the study was amended to allow dose optimization ahead of the Phase 2b study expected to begin in 2H17.

The analyst is encouraged these updates and reiterated his Outperform rating.

No change to the price target of $115.

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $86.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Robert W Baird

Add Your Comment